Lataa...
A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma
PURPOSE: Natural killer (NK) cells may play an important role in the immune response to multiple myeloma (MM); however, MM cells express killer immunoglobulin-like receptor (KIR) ligands to prevent NK cell cytotoxicity. Lenalidomide can expand and activate NK cells in parallel with its direct effect...
Tallennettuna:
| Julkaisussa: | Clin Cancer Res |
|---|---|
| Päätekijät: | , , , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
2015
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4573800/ https://ncbi.nlm.nih.gov/pubmed/25999435 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-0304 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|